Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Having initiated a collaboration with New Jersey-based Medarex last year, Biolex Therapeutics has reported an extension of their agreement to include two additional monoclonal antibodies.
Subscribe to our email newsletter
The collaboration was initially formed in February of 2005 to create the commercial line for the first Medarex antibody using the Biolex Lex System. The expansion of the collaboration comes after the successful achievement of the scientific goals for the first monoclonal antibody.
“We have enjoyed working with Medarex and are very pleased that they are happy with the successful results we have achieved to date with their first monoclonal antibody. We plan to continue building upon and forming similar agreements with other pharmaceutical and biotech companies, while advancing our own pipeline of therapeutic proteins,” said Jan Turek, President and CEO of Biolex.